The Neurologic Oncology Program (Program) is a collection of 17 basic scientists, neuro-oncologists, and neurosurgeons who take a team approach to the improvement of brain cancer therapy. The Program, which has been in existence since the inception of the Helen Diller Family Comprehensive Cancer Center (Center), has as its three programmatic themes: to better understand the underlying biology of brain tumors, to use that information to better predict disease occurrence and outcome, and most importantly, to improve brain tumor therapy. The 17 members of the Neurologic Oncology Program are drawn from seven different UCSF departments, and represent a truly interdisciplinary team. The NCI and other peer-reviewed support for this group of investigators for the 2010-2011 academic year totaled over $23,377,244, including funds to support a P01, T32, and SPORE grants, all specifically designed to pursue and encourage translational brain tumor research. This group of investigators is both highly productive and interactive, as witnessed by the 437 publications of the group in the previous funding period;the multiple publications of the group in leading journals such as Nature, Science, Cancer Cell, Nature Medicine, Nature Genetics, and Neuron;and the high percentage of intra-programmatic (32%) and inter-programmatic (31%) publications. The clinical portion of the Program has been successful developing early phase investigator initiated therapeutic studies and bringing these to the clinic for testing, with particular emphasis on SPORE related clinical trials. The broad range of publications covering population science, cell signaling, genomics, imaging, and clinical science, as well as the high percentage of intra- and inter-programmatic publications, are the result of a strategically Integrated, highly interactive, diverse, and productive Program that continues to make significant progress in reaching its stated goals.
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications